TrialClinical and translational science2024

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design.

Sibel Ucpinar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.